The company has not filed an annual or quarterly report since its Q3 FY2022 10-Q, filed Nov 10, 2022. Its latest SEC filing is a 15-12G from Apr 4, 2023.
10-Q for Q3 FY2022, filed Nov 10, 2022
The sections below describe the company as of the FY2021 annual report.
Develops locally delivered drug treatments for tinnitus and hearing loss for patients with ear disorders.
10-K for FY2021, filed Feb 28, 2022
$125K
10-K for FY2021, filed Feb 28, 2022
$125K ↗No. It lost $51.2M in FY2021.
10-K for FY2021, filed Feb 28, 2022
−$49.6MView ↗
10-K for FY2021, filed Feb 28, 2022
−$51.2MView ↗
10-K for FY2021, filed Feb 28, 2022
−$42.7MView ↗
10-Q for Q3 FY2022, filed Nov 10, 2022
−$12MView ↗
8-K, filed Mar 28, 2023
In accordance with the Plan of Dissolution, the Company has instructed its transfer agent to close the Company’s stock transfer books and…View ↗
8-K, filed Jan 30, 2023
On January 27, 2023, the Company entered into an asset purchase agreement (the “Prevail Agreement”) with Prevail Therapeutics Inc., an…View ↗
8-K, filed Dec 19, 2022
Following Otonomy, Inc.’s (the “Company”) previously announced plans to pause its product development activities and take other steps to…View ↗
Shrank. Revenue fell 90% in 4 years, from $1.2M in FY2017 to $125K in FY2021, about 44% a year.
A former marketed product
The older report described OTIPRIO as approved, commercially launched, and available for purchase; the latest report no longer includes it among current products and focuses on development programs.
10-K for FY2018, filed Mar 4, 2019 10-K for FY2021, filed Feb 28, 2022
A broader hearing-loss pipeline
The older report described three hearing-loss programs, while the latest report adds a gene therapy program for congenital hearing loss and describes four programs targeting different hearing-loss causes.
10-K for FY2018, filed Mar 4, 2019 10-K for FY2021, filed Feb 28, 2022Hearing loss is a large and growing unmet need with estimates by the World Health Organization that more than 360 million people worldwide…View ↗
Hearing loss is a large and growing unmet need with estimates by the World Health Organization that more than 360 million people worldwide…View ↗
OTO-825: GJB2 Gene Therapy Program for Congenital Hearing LossView ↗
OTO-510: Otoprotectant for Cisplatin-Induced Hearing LossView ↗
OTO-6XX: Hair Cell Repair and Regeneration for Severe Hearing LossView ↗
Competes with Altamira Therapeutics, Autifony Therapeutics, Merz Pharmaceuticals GmbH, Novartis, Fennec Pharmaceuticals, Metarmor, Strekin, Sound Pharmaceuticals, Audion Therapeutics, Sensorion, Frequency Therapeutics, Otologic Pharmaceutics, Decibel Therapeutics, Spiral Therapeutics, Pipeline Therapeutics, Akouos, and BridgeBio Pharma
10-K for FY2021, filed Feb 28, 2022There are no drugs currently approved by the FDA for the treatment of tinnitus. Current treatments for tinnitus include the use of audio…View ↗
Loading...
